Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib 2/1 Schedule in Asian Advanced RCC
NCT02626754Phase 2Terminated
- Sponsor
- Taipei Veterans General Hospital
- Start
- Aug 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in renal cell carcinoma (RCC), sponsored by Taipei Veterans General Hospital. Started Aug 2015; status: terminated.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02626754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626754.